{"transactions":[{"id":749844,"issuer":{"id":7770,"kind":"organization","name":"Medicus Pharma Ltd.","symbol":"MDCX"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-04T20:12:40.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year."}],"balance_after":50000,"derivative":{"exercise_price":0.36,"expiration_date":"2031-06-03","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950142-26-001638","document":"es260786890_4-mahaffy.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1997296/000095014226001638/es260786890_4-mahaffy.xml","form_type":"4"}},{"id":823089,"issuer":{"id":7770,"kind":"organization","name":"Medicus Pharma Ltd.","symbol":"MDCX"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-01T23:14:18.000Z","date":"2026-03-30","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":0.5,"exercise_date":"2027-03-26","expiration_date":"2031-03-27","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950142-26-001028","document":"es260758773_4-mahaffy.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1997296/000095014226001028/es260758773_4-mahaffy.xml","form_type":"4"}},{"id":963325,"issuer":{"id":7770,"kind":"organization","name":"Medicus Pharma Ltd.","symbol":"MDCX"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-18T21:08:48.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year."}],"balance_after":25000,"derivative":{"exercise_price":1.8,"expiration_date":"2030-12-16","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950142-25-003236","document":"es250717282_4-mahaffy.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1997296/000095014225003236/es250717282_4-mahaffy.xml","form_type":"4"}},{"id":2354084,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-03T16:15:52.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest on December 31, 2022 if as of such date the Company has sufficient cash and cash equivalents or available sources of borrowings to fund the Company's operating plan, as approved by the Board as of such date, into 2024."}],"balance_after":80000,"derivative":{"exercise_price":1.95,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-22-009061","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924322009061/doc4.xml","form_type":"4"}},{"id":2354083,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-03T16:15:52.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2022 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 2, 2021."}],"balance_after":80000,"derivative":{"exercise_price":1.95,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-22-009061","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924322009061/doc4.xml","form_type":"4"}},{"id":2354082,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-03T16:15:52.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 25% of the shares on March 1, 2023, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date."}],"balance_after":220000,"derivative":{"exercise_price":1.95,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0000899243-22-009061","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924322009061/doc4.xml","form_type":"4"}},{"id":2502597,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-19T10:09:28.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":9.22,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-065713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065713/doc4.xml","form_type":"4"}},{"id":2502596,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-19T10:09:28.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":11.88,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-065713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065713/doc4.xml","form_type":"4"}},{"id":2502595,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-19T10:09:28.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":11.74,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-065713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065713/doc4.xml","form_type":"4"}},{"id":2502594,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-19T10:09:28.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":28.14,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-065713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065713/doc4.xml","form_type":"4"}},{"id":2502593,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-19T10:09:28.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":20.16,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-065713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065713/doc4.xml","form_type":"4"}},{"id":2502592,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-19T10:09:28.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":13.83,"expiration_date":"2026-06-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-065713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065713/doc4.xml","form_type":"4"}},{"id":2502591,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-19T10:09:28.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":21.85,"expiration_date":"2025-06-16","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-065713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065713/doc4.xml","form_type":"4"}},{"id":2502590,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-19T10:09:28.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":17.61,"expiration_date":"2024-03-02","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-065713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065713/doc4.xml","form_type":"4"}},{"id":2502589,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-19T10:09:28.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":39824,"price":8.5,"value":338504.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. (\"Issuer\"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. (\"Purchaser\") (\"Merger Agreement\"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation (\"Merger\"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash (\"Cash Amount\"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 (\"CVR Payments\"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the effective time of the Merger, each outstanding restricted stock unit award (\"RSU\") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-065713","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121065713/doc4.xml","form_type":"4"}},{"id":2653289,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-06-28T18:24:05.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":12500,"derivative":{"exercise_price":9.22,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-043539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121043539/doc4.xml","form_type":"4"}},{"id":2653288,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-28T18:24:05.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan."}],"balance_after":39824,"source":{"system":"sec-edgar","filing":"0001209191-21-043539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121043539/doc4.xml","form_type":"4"}},{"id":2812960,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-03T18:39:21.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shall vest upon the enrollment of three dose cohorts in the Company's LuMIERE study on or before December 31, 2021."}],"balance_after":40000,"derivative":{"exercise_price":6.23,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-21-009499","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924321009499/doc4.xml","form_type":"4"}},{"id":2812959,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-03T18:39:21.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest upon the selection of an alpha-emitter agent for use in the study of the Company's product candidate FAP-2286 on or before December 31, 2021."}],"balance_after":40000,"derivative":{"exercise_price":6.23,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-21-009499","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924321009499/doc4.xml","form_type":"4"}},{"id":2812958,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-03T18:39:21.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2021 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 8, 2020."}],"balance_after":80000,"derivative":{"exercise_price":6.23,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-21-009499","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924321009499/doc4.xml","form_type":"4"}},{"id":2812957,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-03T18:39:21.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 25% of the shares on March 1, 2022, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date."}],"balance_after":220000,"derivative":{"exercise_price":6.23,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0000899243-21-009499","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924321009499/doc4.xml","form_type":"4"}},{"id":3111666,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-06-12T16:24:24.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":12500,"derivative":{"exercise_price":11.88,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-20-036278","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120036278/doc4.xml","form_type":"4"}},{"id":3111665,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T16:24:24.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan."}],"balance_after":35324,"source":{"system":"sec-edgar","filing":"0001209191-20-036278","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120036278/doc4.xml","form_type":"4"}},{"id":3266730,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-18T19:27:45.000Z","date":"2020-02-13","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in the event the Company's Product Revenues for the Company's fiscal year ending December 31, 2020 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board of Directors on February 13, 2020."}],"balance_after":50000,"derivative":{"exercise_price":9.71,"expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-20-004963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924320004963/doc4.xml","form_type":"4"}},{"id":3294851,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-03T17:05:24.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest upon the submission by the Company to the FDA of an IND for FAP-2286 on or before December 31, 2020."}],"balance_after":50000,"derivative":{"exercise_price":8.39,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-20-002563","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924320002563/doc4.xml","form_type":"4"}},{"id":3294850,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-03T17:05:24.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 25% of the shares on January 31, 2021, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date."}],"balance_after":200000,"derivative":{"exercise_price":8.39,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-20-002563","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924320002563/doc4.xml","form_type":"4"}},{"id":3426628,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-08-29T16:46:03.000Z","date":"2019-08-29","kind":"exercise","acquired":false,"shares":30824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.16,"expiration_date":"2019-09-23","underlying":"Common Stock","underlying_shares":30824},"source":{"system":"sec-edgar","filing":"0001209191-19-047709","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119047709/doc4.xml","form_type":"4"}},{"id":3426627,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-29T16:46:03.000Z","date":"2019-08-29","kind":"exercise","acquired":true,"shares":30824,"price":0.16,"value":4931.84,"ownership":{"direct":true},"balance_after":30824,"source":{"system":"sec-edgar","filing":"0001209191-19-047709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119047709/doc4.xml","form_type":"4"}},{"id":3434470,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-19T08:35:30.000Z","date":"2019-08-16","kind":"purchase","acquired":true,"shares":5827,"price":5.6,"value":32631.2,"ownership":{"direct":true},"balance_after":968787,"source":{"system":"sec-edgar","filing":"0000899243-19-022005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319022005/doc4.xml","form_type":"4"}},{"id":3434469,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-19T08:35:30.000Z","date":"2019-08-16","kind":"purchase","acquired":true,"shares":5100,"price":5.6,"value":28560.0,"ownership":{"direct":true},"balance_after":962960,"source":{"system":"sec-edgar","filing":"0000899243-19-022005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319022005/doc4.xml","form_type":"4"}},{"id":3434468,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-19T08:35:30.000Z","date":"2019-08-16","kind":"purchase","acquired":true,"shares":11053,"price":5.59,"value":61786.27,"ownership":{"direct":true},"balance_after":957860,"source":{"system":"sec-edgar","filing":"0000899243-19-022005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319022005/doc4.xml","form_type":"4"}},{"id":3434467,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-19T08:35:30.000Z","date":"2019-08-16","kind":"purchase","acquired":true,"shares":3700,"price":5.59,"value":20683.0,"ownership":{"direct":true},"balance_after":946807,"source":{"system":"sec-edgar","filing":"0000899243-19-022005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319022005/doc4.xml","form_type":"4"}},{"id":3434466,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-19T08:35:30.000Z","date":"2019-08-16","kind":"purchase","acquired":true,"shares":11314,"price":5.58,"value":63132.12,"ownership":{"direct":true},"balance_after":943107,"source":{"system":"sec-edgar","filing":"0000899243-19-022005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319022005/doc4.xml","form_type":"4"}},{"id":3434465,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-19T08:35:30.000Z","date":"2019-08-16","kind":"purchase","acquired":true,"shares":6400,"price":5.61,"value":35904.0,"ownership":{"direct":true},"balance_after":931793,"source":{"system":"sec-edgar","filing":"0000899243-19-022005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319022005/doc4.xml","form_type":"4"}},{"id":3434464,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-19T08:35:30.000Z","date":"2019-08-16","kind":"purchase","acquired":true,"shares":2100,"price":5.61,"value":11781.0,"ownership":{"direct":true},"balance_after":925393,"source":{"system":"sec-edgar","filing":"0000899243-19-022005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319022005/doc4.xml","form_type":"4"}},{"id":3434463,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-19T08:35:30.000Z","date":"2019-08-16","kind":"purchase","acquired":true,"shares":3706,"price":5.57,"value":20642.42,"ownership":{"direct":true},"balance_after":923293,"source":{"system":"sec-edgar","filing":"0000899243-19-022005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319022005/doc4.xml","form_type":"4"}},{"id":3434462,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-19T08:35:30.000Z","date":"2019-08-16","kind":"purchase","acquired":true,"shares":400,"price":5.58,"value":2232.0,"ownership":{"direct":true},"balance_after":919587,"source":{"system":"sec-edgar","filing":"0000899243-19-022005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319022005/doc4.xml","form_type":"4"}},{"id":3434461,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-08-19T08:35:30.000Z","date":"2019-08-16","kind":"purchase","acquired":true,"shares":400,"price":5.56,"value":2224.0,"ownership":{"direct":true},"balance_after":919187,"source":{"system":"sec-edgar","filing":"0000899243-19-022005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319022005/doc4.xml","form_type":"4"}},{"id":3481219,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-06-21T16:02:34.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":18000,"derivative":{"exercise_price":11.74,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-19-038447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119038447/doc4.xml","form_type":"4"}},{"id":3677389,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-04T18:01:01.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in the event the Company's Product Revenues for the Company's fiscal year ending December 31, 2019 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board of Directors on December 6, 2018."}],"balance_after":100000,"derivative":{"exercise_price":25.75,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-19-002504","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319002504/doc4.xml","form_type":"4"}},{"id":3677388,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-04T18:01:01.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 25% of the shares on February 1, 2020, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date."}],"balance_after":200000,"derivative":{"exercise_price":25.75,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-19-002504","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924319002504/doc4.xml","form_type":"4"}},{"id":3886001,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-06-21T16:08:21.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":18000,"derivative":{"exercise_price":28.14,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-18-038928","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118038928/doc4.xml","form_type":"4"}},{"id":4019941,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2018-03-02T18:25:44.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 25% of the shares on March 1, 2019, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date."}],"balance_after":120000,"derivative":{"exercise_price":58.43,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000899243-18-006219","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924318006219/doc4.xml","form_type":"4"}},{"id":4249996,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-27T09:34:01.000Z","date":"2017-06-22","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":18000,"derivative":{"exercise_price":20.16,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-17-046387","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919117046387/doc4.xml","form_type":"4"}},{"id":4255152,"issuer":{"id":157016,"kind":"organization","name":"Orexigen Therapeutics, Inc.","symbol":"OREXQ"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-18T23:46:32.000Z","date":"2017-07-14","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer."}],"balance_after":5000,"derivative":{"exercise_price":2.88,"expiration_date":"2027-07-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-17-045603","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266569/000120919117045603/doc4.xml","form_type":"4"}},{"id":4370304,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2017-03-28T18:49:31.000Z","date":"2017-03-27","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 12.5% of the shares on March 1, 2018, and as to 37.5% of the shares in substantially equal installments over the 36 months immediately following such date. The option shall vest as to 50% of the shares upon the approval by the U.S. Food & Drug Administration of a supplemental NDA for second-line maintenance therapy for Rubraca based on data from the ARIEL3 trial."}],"balance_after":150000,"derivative":{"exercise_price":68.31,"expiration_date":"2027-03-27","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-17-008769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924317008769/doc4.xml","form_type":"4"}},{"id":4599972,"issuer":{"id":122635,"kind":"organization","name":"Clovis Oncology, Inc.","symbol":"CLVS"},"owners":[{"id":41404,"kind":"person","name":"MAHAFFY PATRICK J","position":1,"cik":"0001266569","reported_name":"MAHAFFY PATRICK J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2016-09-19T18:12:14.000Z","date":"2016-09-16","kind":"other","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person voluntarily forfeited the option as to 25,000 of the shares, which was subject to vesting upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rociletinib.  Following such forfeiture, the Reporting Person holds the option as to the remaining 75,000 shares (the \"Remaining Shares\").  The option vested as to 12,500 of such Remaining Shares on March 2, 2016 and has vested or will vest as to 37,500 of such Remaining Shares in substantially equal installments over the 12 quarters immediately following such date.  The option shall vest as to 25,000 of such Remaining Shares upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rucaparib."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person voluntarily forfeited the option as to 25,000 of the shares, which was subject to vesting upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rociletinib.  Following such forfeiture, the Reporting Person holds the option as to the remaining 75,000 shares (the \"Remaining Shares\").  The option vested as to 12,500 of such Remaining Shares on March 2, 2016 and has vested or will vest as to 37,500 of such Remaining Shares in substantially equal installments over the 12 quarters immediately following such date.  The option shall vest as to 25,000 of such Remaining Shares upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rucaparib."}],"balance_after":75000,"derivative":{"exercise_price":79.05,"expiration_date":"2025-03-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-16-029283","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466301/000089924316029283/doc4.xml","form_type":"4"}}]}